ライフサイエンスコーパス: P value

1 : p = 0.002; well-being: p = 0.002; adjusted p-values).

2 : p < 0.001; well-being: p < 0.001; adjusted p-values).

3 ta are presented as mean difference (CI) and p value.

4 ysis, updated data are reported with nominal p values.

5 nstandardized (B) coefficients, 95% CIs, and P values.

6 P value using Fisher's method for combining P values.

7 results are provided with two-sided, nominal p values.

8 erent [Formula: see text] value and multiple p values.

9 tween hits rotational acceleration (adjusted p value 0.0101), and time until DTI rotational accelerat

10 ], P=0.025) and lower survival rates (global P value 0.029; >75% Hispanic: odds ratio, 0.56 [CI, 0.34

11 59; ever smoking OR 1.10 (95% CI 1 to 1.23), p value 0.05.

12 etime smoking OR 0.94 (95% CI 0.74 to 1.19), p value 0.59; ever smoking OR 1.10 (95% CI 1 to 1.23), p

13 of AD observed in the FLG LOF carrier group (p-value 0.0003, Wilcoxon two-sample test).

14 pi-PTB (RR(adj) 8.12, 95% CI [2.54-25.93], p-value 0.007), maternal weight gain between 20 and 27 w

15 (46/2,273), (RR 0.52 [95% CI 0.32 to 0.85], p-value 0.009, RD -97/10,000 [95% CI -169/10,000 to -26/

16 eeks <p10 (RR(adj) 2.04, 95% CI [1.23-3.38], p-value 0.018) and participants from the Northeast centr

17 odds ratio [OR] 0.21 [95% CI 0.06 to 0.78], p-value 0.019, RD -31/10,000, [95% CI -56/10,000 to -5/1

18 [95% confidence interval [CI] 0.21 to 0.91], p-value 0.027, risk difference [RD] -57/10,000 [95% CI -

19 t centres (RR(adj) 2.35, 95% CI [1.11-4.95], p-value 0.034) were independently associated with APO.

20 ignificance detected between the two groups (p-value 0.246).

21 ersus 10.7%; RR 0.98, [95% CI 0.83 to 1.16], p-value 0.81) nor in other important perinatal, delivery

22 0.0115, and 0.0473 respectively, competitive-P-values 0.0029, 0.0002, and 0.0045 respectively).

23 d TS samples and replicated the association (P value = 0.001).

24 al pre-pregnancy BMI (mediation effect: 64%; P value = 0.001).

25 The most frequently broken motif was REST (p value = 0.0028), which has been reported as both a tum

26 therosclerosis (OR = 2.4, 95% CI, 1.41-4.07, P value = 0.003).

27 f preterm birth (OR 1.08 [95% CI 1.02-1.15], P value = 0.012), small size for gestational age (OR 2.1

28 nce, TOST confidence interval, -1.8 +1.6 PD, P value = 0.014).

29 95% confidence interval) of 1.54 (1.06-2.24; P value = 0.02), whereas for the previous-CVD phenotype,

30 r JNJ-42165279 (44.1%) than for PBO (23.6%) (p value = 0.02).

31 at position 248 at time points 7 (OR = 11.5; P value = 0.03) and 28 (OR = 9.0; P value = 0.05) was ob

32 ht (odds ratio [OR] 1.17 [95% CI 1.02-1.35], P value = 0.030).

33 95% confidence interval [CI], -6.5 to -0.2%, P value = 0.04) and relative difference of -17% (95% CI,

34 NJ-42165279 (42.4%) compared to PBO (23.6%) (p value = 0.04).

35 OR = 11.5; P value = 0.03) and 28 (OR = 9.0; P value = 0.05) was observed in the ENR group when compa

36 ative difference of -17% (95% CI, -34 to 0%, P value = 0.05).

37 an adjusted hazard ratio of 0.69 (0.46-1.04; P value = 0.08).Conclusions: For patients with ACS and a

38 control studies was 0.70 (95% CI 0.57-0.86, (P-value = 0.00).

39 5 (95% CI 0.41-0.73), which was significant (P-value = 0.00).

40 ide the cardiac sarcolemma (Hi-C interaction p-value = 0.00002).

41 tion error than the PBMC-based DNAm markers (p-value = 0.0002).

42 es was lower [RR 0.89, 95% CI: 0.83 to 0.96, p-value = 0.002].

43 m 0.98 +/- 0.22 to 0.45 +/- 0.25 in Group 2 (P-value = 0.005) at 6 months.

44 type patients (HR = 4.44, 95% CI:1.23-16.13, p-value = 0.005), which validated in two independent cli

45 3%, arm BMD P-value = 0.12, forearm fracture P-value = 0.005).

46 pooled OR: 2.63; 95% CI: 1.35-5.11; I2: 67%; p-value = 0.01), dysuria (3,686 FGM/C and 3,482 non-FGM/

47 pooled OR: 1.43; 95% CI: 1.17-1.75; I2: 0%; p-value = 0.01), episiotomy (29,341 FGM/C and 39,260 non

48 ctal cancer (OR: 0.66, 95% CI: 0.48 to 0.90, P-value = 0.01).

49 h postoperative BCVA at 6 months (r = 0.562; P-Value = 0.01, forward stepwise regression analysis).

50 roma (P-value < 0.0001) and total intensity (P-value = 0.011) values.

51 higher with the inverted ILM flap technique (P-value = 0.02).

52 ts) was statistically higher in the Group 2 (P-value = 0.03).

53 95% confidence interval [CI]: 0.27 to 0.98, P-value = 0.04) and colorectal cancer (OR: 0.66, 95% CI:

54 confidence interval (CI)], 1.71 [1.03-2.85]; P-value = 0.040).

55 o = 2.74; 95% confidence interval 1.01-7.40, p-value = 0.047)-after adjusting for age, time period (b

56 ed BMD P-value = 1.2 x 10(-16), any fracture P-value = 0.05) and 375,984 Icelandic samples (MAF = 0.0

57 ted odds ratio [aOR] 1.13, 95% CI 0.97-1.32, p-value = 0.105).

58 ,984 Icelandic samples (MAF = 0.03%, arm BMD P-value = 0.12, forearm fracture P-value = 0.005).

59 but this was not statistically significant (P-value = 0.6510).

60 y-equipped heating-stoves (strata difference p-values = 0.001, 0.003, and 0.094, respectively).

61 are than women (OR: 0.39; 95% CI: 0.22-0.67; p-value: 0.001).

62 associated with PR (Fold Change: 0.91-1.27, p-value: 0.004-0.05).

63 f P-gp inhibitors or substrates (interaction p-value: 0.029).

64 Child-Pugh B cirrhosis (CTP 7-9) were IP-10 (p-value= 0.008) and IL-6 (p-value=0.002).

65 0.41) and OR HP2-1 0.5, 95% CI 0.28 to 0.89 (p value=0.02) (overall p value=0.06).

66 95% CI 0.28 to 0.89 (p value=0.02) (overall p value=0.06).

67 follows: OR HP1-1 0.73, 95% CI 0.34 to 1.56 (p value=0.41) and OR HP2-1 0.5, 95% CI 0.28 to 0.89 (p v

68 .86 [95% CI, 0.66-1.11]; P=0.34; interaction P value=0.80).

69 .02 [95% CI, 0.73-1.41]; P=0.58; interaction P value=0.89).

70 P 7-9) were IP-10 (p-value= 0.008) and IL-6 (p-value=0.002).

71 nversely associated with AD risk (OR = 0.40; P-value = .004).

72 bles, age, and inter-individual variability (P-values .007, .018, and .058, respectively).

73 observed with increasing number of siblings (P-value = .023), the protective effect reaching about 40

74 children with 2 or more siblings (OR = 0.62; P-value = .048).

75 mpared to CS with or without labor (adjusted p-value 1.57 x 10(-11) and 3.70 x 10(-13), respectively)

76 40, 95% confidence interval (CI), 0.04-0.47, P value = 1.72 x 10-28), triglycerides (TRG) (beta -0.23

77 x 10(-13)), neurofibrillary tangle density (p value = 1.89 x 10(-6)), and global measure of AD patho

78 failure (HF) (OR = 1.61, 95% CI, 1.32-1.95, P value = 1.9 x 10-6), and large artery atherosclerosis

79 ated with increased azithromycin resistance (p-value = 1.08 x 10(-11)).

80 435 UK (MAF = 0.05%, heel bone estimated BMD P-value = 1.2 x 10(-16), any fracture P-value = 0.05) an

81 ts (genome-transcriptome correlation = 0.35, p-value = 1.2e-14).

82 ion of phenotypic variance for height (0.15, p-value = 1.5e-283), and that these transcriptomic effec

83 (P-value = 4.2 x 10(-5)) and fracture risk (P-value = 1.6 x 10(-5)).

84 30-31) and atherosclerosis signaling (- log[P-value] = 10-11) were similarly affected in Cbs(-/-) mi

85 CBS(-/-) humans than in Cbs(-/-) mice (- log[P-value] = 15 vs. 10, respectively) while acute phase re

86 including MI (OR = 1.84, 95% CI, 1.43, 2.37, P value = 2.0 x 10-6), CHD (OR = 1.64, 95% CI, 1.28-2.09

87 ated with decreased ultradistal forearm BMD (P-value = 2.1 x 10(-18)), and increased osteoporosis (P-

88 ghest association with reduced FHR-4 levels (P-value = 2.2 x 10(-56)), independently of the AMD-prote

89 n chromosome 20, were identified: rs4809706 (p-value: 2.8 x 10(-8)), rs4810824 (p-value: 3.5 x 10(-8)

90 and 22, respectively) than in humans (- log[P-value] = 22 and 6, respectively).

91 significantly associated with beta-amyloid (p value = 3.44 x 10(-8)) which was driven by both cis- a

92 forest analysis shows profound (AUC = 0.92, p-value = 3.16E-8) MP-induced alterations of immune cell

93 s4809706 (p-value: 2.8 x 10(-8)), rs4810824 (p-value: 3.5 x 10(-8)), and rs6019297 (p-value: 4.7 x 10

94 , such as LXR/RXR, FXR/RXR activation (- log[P-value] = 30-31) and atherosclerosis signaling (- log[P

95 re affected stronger in Cbs(-/-) mice (- log[P-value] = 33 and 22, respectively) than in humans (- lo

96 des (TRG) (beta -0.23, 95% CI, -0.30, -0.15, P value = 4.69 x 10-10), automated systolic blood pressu

97 ) measurement (beta 0.11, 95% CI, 0.03-0.18, P value = 4.72 x 10-3), and automated diastolic BP measu

98 2.1 x 10(-18)), and increased osteoporosis (P-value = 4.2 x 10(-5)) and fracture risk (P-value = 1.6

99 0824 (p-value: 3.5 x 10(-8)), and rs6019297 (p-value: 4.7 x 10(8)).

100 P measurement (beta 0.09, 95% CI, 0.03-0.16, P value = 5.24 x 10-3).

101 gher k(3) (p value = 8.8 x 10(-8)) and K(i) (p value = 5.3 x 10(-8)) than normal nodes.

102 ReX) of ZC3H12B and Alzheimer dementia (AD) (p value = 5.42 x 10(-13)), neurofibrillary tangle densit

103 atherosclerosis (OR 1.02, 95% CI, 1.01-1.03, P value = 5.56 x 10-4).

104 estive associations between SNPs, rs6880062 (p-value: 5.4 x 10(-8)) and rs6880461 (p-value: 9.5 x 10(

105 reased TRG (beta 0.097, 95% CI, 0.014-0.027, P value = 6.59 x 10-12).

106 ficant burden for VPS16 (Fisher's exact test p value, 6.9 x 10(9) ).

107 t systemic FHR-4 levels are elevated in AMD (P-value = 7.1 x 10(-6)), whereas no difference is seen f

108 x 10-6), CHD (OR = 1.64, 95% CI, 1.28-2.09, P value = 8.07 x 10-5), heart failure (HF) (OR = 1.61, 9

109 astatic nodes had significantly higher k(3) (p value = 8.8 x 10(-8)) and K(i) (p value = 5.3 x 10(-8)

110 10(-6)), and global measure of AD pathology (p value = 9.59 x 10(-7)).

111 80062 (p-value: 5.4 x 10(-8)) and rs6880461 (p-value: 9.5 x 10(-8)), and suicide attempt were identif

112 -05 in all GWAS data sets and that SNPs with P-values above 0.2 were inflated for SLE true positive s

113 o be run sequentially to yield anytime-valid P values and confidence sequences.

114 e favorable performance compared to ordering P-values and a number of other competing ranking methods

115 ucose response genes among small association p-values and identified folliculin (FLCN) as a susceptib

116 studies using Z-scores, modified Z'-scores, p-values and Jaccard indices.

117 are presented as relative risk (95% CIs) and p value, and continuous data are presented as mean diffe

118 used a recursive application of the minimum P value approach with univariate competing risk regressi

119 ds, with 28 novel experimental aliphatic log P values, are involved in discussing various lipophilici

120 We report an increase of 30% in significant P-values, as well as linkage to 106 versus 99 disease mo

121 es statistically valid test with appropriate p-values, (b) provides confidence intervals for differen

122 Often, the final analysis focuses on a P-value-based ranking of locations which might then be i

123 y may result in small effect sizes, with low P-values, being ranked more favorably than larger more s

124 ically significant at a Bonferroni corrected p-value below 0.0013.

125 did not observe changes in plant delta(18)O(P) value, but soil P delta(18)O(P) values changed, and l

126 on to increase the accuracy and speed of the P-value calculation.

127 t delta(18)O(P) value, but soil P delta(18)O(P) values changed, and lower delta(18)O(P) values were a

128 ls using functional norms and a novel robust p value combination test.

129 tly, AW-Fisher suffers from the lack of fast P-value computation and variability estimate of AW weigh

130 sed by multivariable linear regression, with p-values corrected using the Benjamini-Hochberg approach

131 der follow-up intervals (6%; 95% CI, 2%-13%; P value for interaction = .01).

132 and baseline eGFR on odds for incident AKI (P value for interaction = 0.75).

133 t-label change), 0.85; 95% CI, 0.83 to 0.88; P value for interaction by period <0.001).

134 bel change (aPR, 0.90; 95% CI, 0.74 to 1.09; P value for interaction by period =0.04).

135 e tract was 1.13 (95% CI, 1.01 to 1.26), the P value for interaction comparing women with vs without

136 -1.08] in patients without a history of CVD; P value for interaction, 0.85).

137 the ICD benefit was observed after 6 years (p value for the interaction = 0.0015).

138 score (pooled HR: 0.72, 95% CI: 0.59, 0.87; P value for trend <0.001).

139 d with graded, higher odds of AKI incidence (P value for trend <0.001); however, there was no interac

140 amputation (19.8% in 2005 to 12.9% in 2014; P value for trend <0.01 for both) at 90 days.

141 creased from 47.4% in 2005 to 60.9% in 2014 (P value for trend <0.01).

142 ak 30 cadence: HR, 0.90 [95% CI, 0.65-1.27]; P value for trend = .34).

143 ons and bleeding events decreased over time (P value for trend test <0.0001); however, there was sign

144 person-years; HR, 1.69 [95% CI, 1.47-1.94]; P values for heterogeneity comparing 18-39 years with 40

145 87% to 100%) with 8 and 16 mg, respectively (p values for responders >85% target; p = 0.142 and p = 0

146 very week, as compared with 6% with placebo (P values for the comparison with placebo ranged from 0.0

147 ther selection criterion to calculate the BH p-value for the respective estimates.

148 dependency on both time and temperature, the p-value for the time variable was much smaller in most c

149 0.97 (95% confidence interval: 0.87 to 1.08, P-value for trend = 0.61).

150 he DNA methylome and calculated Fisher-exact p-values for a series of univariate tests.

151 hat combines betweenness values and adjusted p-values for target inference.

152 Adjusted odds ratios (95% CI; p-value) for infant deaths were significantly increased

153 The GWAS identified 28 significant SNPs at p-value [Formula: see text] significance level and we pi

154 on an intention-to-treat basis and obtained P values from analyses in the uni- and bilateral groups

155 e for 94 journals over a 5-year period using p values from over 30,000 abstracts enabling the study o

156 nalysis, is an effective approach to combine P-values from K independent studies and to provide bette

157 ctrum of parameter values, as graphed in the P value function.

158 The mean (SD, [95% confidence interval], P value) gain in best-corrected visual acuity (BCVA) fro

159 approaches: randomly, evenly spaced, lowest p value (genome-wide association or epigenome-wide assoc

160 els when using the averaged reader data (all P values > 0.103).

161 e the compensation strategy was applied (all P values >.22).

162 nt, 6 motifs have modest or no associations (P values >0.05), and 1 motif has 7 copies observed among

163 d with the number of courses of antibiotics (P-value > 0.05), but it was significantly associated wit

164 one was found with the addition of steroids (P-value > 0.05).

165 wed no statistically significant difference (p-value > 0.05).

166 (P-values > 0.42) nor associated with APOE (P-values > 0.13).

167 ions were not significant (r = 0.05 to 0.26, P-values > 0.27).

168 orrelated with clinical Alzheimer's disease (P-values > 0.42) nor associated with APOE (P-values > 0.

169 ion stepdown (adjusted hazard ratio, 95% CI, p-value: ICS inhaler dose = 0.86, 0.77-0.93, p < 0.001;

170 prescriptions (adjusted odds ratio, 95% CI, p-value: ICS inhaler dose = 0.99, 0.98-1.00, p = 0.59; I

171 But the proclivity to degrade P values into dichotomous bins corresponding to statisti

172 used to identify the determinant factors and p value less than 0.05 was considered as statistically s

173 A P value less than 0.05 was considered statistically sign

174 Statistical significance was defined as a p value less than 0.10, due to the small number of patie

175 associated with asthma hospitalizations at a P value less than 1 x 10(-6).

176 Two-tailed t tests were used and P values less than .05 were considered to indicate stati

177 metagenome sequence data is significant with P-values less than 4.04E-17.

178 ehensive Meta-Analysis Software Ver.2, while p-value lower than 0.05 was considered significant.

179 raclass correlation) were performed, where a P value < .05 was considered significant.

180 A P value < .05 was considered significant.

181 A P value < .05 was considered statistically significant.

182 idities, DM complications, and hypertension (P value < .05).

183 general psychopathology factor and ~ 0.50% (p value < 0.0001) in specific hyperactivity/impulsivity.

184 ADHD PRS explained ~ 1% (p value < 0.0001) of the variance in the general psychop

185 ical remission as compared to the active RA (p value < 0.0001).

186 hood overweight (OR 1.21 [95% CI 1.16-1.27], P value < 0.001) but not with adverse birth outcomes.

187 gestational age (OR 2.15 [95% CI 2.07-2.23], P value < 0.001), and childhood overweight (OR 1.42 [95%

188 hood overweight (OR 1.42 [95% CI 1.35-1.48], P value < 0.001).

189 rational association (mediation effect: 99%; P value < 0.001).

190 nificant higher odds 4.86 (95% CI, 1.4-12.8, P value < 0.009) of histologic response, including signi

191 statistic index > 25%, Cochrane Q statistic p value < 0.05), random-effects model was used.

192 cell ratio demonstrates the similar result (p value < 0.05).

193 onditionally independent SNPs were detected (p value < 6.6 x 10(-9)) among which 53 had MAF < 5%.

194 and late ("metastatic") stage cancer with a p value <0.0001.

195 CD38, HLADR, or Ki67 compared with LTBI (all P values < .001).

196 rformance outcomes across all 3 time points (P values < .001).

197 from the small to large research group (all p values < .001).

198 s (35.6% and 26.8% reductions, respectively; P values < .001).

199 nts were associated with 1.30- to 2.36-fold (p values < .02) increased relative risk for higher numbe

200 ART initiation (Benjamini-Hochberg corrected P values < .02).

201 a peer interventionist (aHRs, 1.35 to 1.72; P values < .05 for all).

202 adjusted hazard ratios [aHRs], 1.34 to 1.40; P values < .05 for both).

203 , and thigh circumference, respectively (all P values < .05).

204 were more likely to have to have an ACO (all P values < .05).

205 ults, and concurrent asthma medications (all P values < .05).

206 r declines in FEV1:FVC ratio (r = 0.11) (all P values < 0.0001).

207 MA-B, hs-CRP, and eGFR than white women (all P values < 0.0001).

208 efficients = -0.111 to -0.068, FDR corrected P values < 0.039) and were significantly negatively corr

209 332Val] and c.752T>C [p.Met251Thr]) yielding p values < 10(-10).

210 V [PLWHIV]) showed suggestive evidence, with P values < 10-3; only 3 (5.5%; higher prevalence of coug

211 95 [95% CI: 1.55 to 2.45] for the PNI score; p values <0.001 for all nutritional indexes).

212 and status 6 (-8%) candidates than expected (p values <0.01 for all comparisons).

213 s showed responsiveness to change over time (p values <0.05), as did nine of 15 single symptom items.

214 , and 2.95 [1.20 to 7.24], respectively; all P values <0.05).

215 ty and learning, memory, and motor function (P values <0.05).

216 es of both animal and vegetable protein (all P values <= 0.01).

217 oma Scale (GCS) score <13, and seizures (all P values <=0.01).

218 gs had higher a* (P-value < 0.0001), chroma (P-value < 0.0001) and total intensity (P-value = 0.011)

219 ted that Apulo-Calabrese pigs had higher a* (P-value < 0.0001), chroma (P-value < 0.0001) and total i

220 lusters differ significantly for OS and RFS (p-value < 0.0001).

221 es for both PM(2.5) [slope = 0.47 (+/-0.03); p-value < 0.0001] and PM(10) [slope = 0.46 (+/-0.09); p-

222 0.0001] and PM(10) [slope = 0.46 (+/-0.09); p-value < 0.0001] samples.

223 95% confidence intervals (CI) (0.70, 0.82), P-value < 0.0001].

224 y average precision (MAP): 0.28 versus 0.23, P-value < 0.0001].

225 nce interval [CI] 2.15-2.48; 1.67% vs 0.83%; p-value < 0.001), 1.35 (95% CI 1.30-1.40; 1.08% vs 0.83%

226 01), 1.35 (95% CI 1.30-1.40; 1.08% vs 0.83%; p-value < 0.001), and 1.37 (95% CI 1.21-1.54; 1.74% vs 0

227 sequent 60 days (aOR 1.17, 95% CI 1.09-1.26, p-value < 0.001), but there was limited evidence that in

228 and 1.37 (95% CI 1.21-1.54; 1.74% vs 0.83%; p-value < 0.001), respectively.

229 ignificantly lower in clams than in mussels (p-value < 0.001), with Danish mussels having the highest

230 [rate ratio (RR) 1.25, 95% CI: 1.16 to 1.35, p-value < 0.001], while risk among females was lower [RR

231 pooled OR: 1.89; 95% CI: 1.26-2.82; I2: 96%; p-value < 0.01), and prolonged labor (7,516 FGM/C and 8,

232 onfidence interval [CI]: 1.45-4.21; I2: 79%; p-value < 0.01), perineal tears (4,898 FGM/C and 4,229 n

233 pooled OR: 2.04; 95% CI: 1.27-3.28; I2: 90%; p-value < 0.01).

234 ross both brain and serum diagnostic groups (P-value < 0.05).

235 ted with resistance to numerous antibiotics (p-value < 0.05).

236 mong phage susceptible A. baumannii strains (p-value < 0.05).

237 th increased number of postoperative visits (P-value < 0.05).

238 s, the levels of two differed significantly (p-value < 0.05, FC > 1.5) in CD patients and controls, a

239 The levels of 13 miRNAs differed (p-value < 0.05; FC > 1.5) in CD patients and controls be

240 ification (OR = 106.15, 95% C.I = 70.66-Inf, P-value < 2.2 x 10(-16)).

241 nt almost doubled to 0.82 (range: 0.74-0.87; P-value <0.0001).

242 s <=0.001) and segmental glomerulosclerosis (p-value <0.0001).

243 al change in aggregation rate upon mutation (P-value <0.0001).

244 tio 2.26, 95% confidence interval 1.47-3.46, p-value <0.001) compared to patients without lymphopenia

245 us no SSB consumption was 1.32 (1.10, 1.57); p-value <0.001.

246 ay versus no consumption: 0.82 (0.76, 0.87); p-value <0.001], whereas other juices were associated wi

247 ay versus no consumption: 1.15 (1.03, 1.28); p-value <0.001].

248 ed with responses of 33 metabolite measures (P-value <1.34x10(-3)), mainly smaller increases of the T

249 y DArTseq SNPs revealed 15 significant SNPs (P-value <10(-3)) on chromosomes 2D, 3B, 4D and 7B that w

250 d better treatment response to azithromycin (P-values < .05).

251 wever, 19 non-synonymous showed conventional P-values < 0.05 comparing the frequency of the alleles b

252 n of genes with top nominal eQTL association p-values < 10-7.

253 g sex-specific effects on asthma transition (P-values <.01 in both cohorts).

254 e were found at 13 of the 535 CpGs in IOWBC (P-values <1.0 x 10(-3) ).

255 year-olds (respective aRRs 1.79, 2.33, 1.92; p-values <= 0.002).

256 erulitis, peritubular capillary infiltrates; p-values <=0.001) and segmental glomerulosclerosis (p-va

257 ciated with glomerular area in both cohorts (p-values <=0.001).

258 s showed stronger evidence using a stringent P value (<10-6).

259 with CEE+MPA (false discovery rate-adjusted P value<0.05) in multivariable models.

260 stablished CA125 chemiluminiscent ELISA with P-value<0.0001.

261 creased total IgA (sdCOVID, P=0.01; scCOVID, p-value<0.001), but not total IgG.

262 ted Hazard Ratio aHR 0.70, 95% CI 0.54-0.91, p-value<0.01), but not associated with transplant list d

263 erular area was associated with higher eGFR (p-value<=0.001) and increased graft survival after accou

264 with widespread misinterpretation of what a P value measures, is reason to seek an alternative that

265 it did not reach significance at a critical P value of .009.

266 ciated with severe asthma exacerbations at a P value of .01 or less in the same direction of associat

267 s, and a significance threshold was set to a P value of .05.

268 A P value of 0.006 was set as significant after Bonferroni

269 are was used for statistical analysis with a P value of less than .05 considered a significant differ

270 and group 3, 0.93 (95% CI: 0.88, 0.97), with P values of .0006 and < .0001, respectively.

271 0.65 (range, 0.44-1.43) for benign lesions (P values of .01, .02, < .001, respectively).

272 The p values of less than 0.05 were considered statistically

273 Variables with p values of less than 0.1 were considered for logistic r

274 systematically analyzes the distribution of P values of primary outcomes for phase II and phase III

275 an unexpected high flexibility in C:N and C:P values of saprobic fungi along nutrient supply gradien

276 unpaired two-tailed Student's t-test and the p-value of < 0.05 was deemed as statistically significan

277 ence level was determined and variables with p-value of < 0.05 were considered as statistically signi

278 ntral macular thickness after 6 months, with p-values of 0.135 and 0.145, respectively.

279 the x-axis and the negative log-10 of their p-value on the y-axis.

280 8 out of 26 traits, each with an interaction P-value (${{P}}_{{INT}}$) less than $0.05/104={0.00048}$

281 ihood ratio (LR) test was conducted, and its P values, P(LR), for rs10947231 and rs8192575 were 2.23

282 Selected SCZ GWAS association P values play the role of the primary data for AdaPT; si

283 ent of C1-C4 survived Bonferroni correction (P value range, .007-.04), with a higher percentage lesio

284 erences in tumor characteristics were found (P values ranging from .22 to .95).

285 icantly associated with sarcopenia (combined p-values ranging from 5.92 x 10(-12) to 1.69 x 10(-9)).

286 P values should be used sparingly; in most cases, report

287 nding covariates, and uses permutation-based P-values that can control for sample correlation.

288 help to avoid the worst practices regarding P values-the tendency to dichotomize them into significa

289 aches such as linkage disequilibrium pruning/p value thresholding (fixed or data-adaptively optimized

290 for major depression (MD) at different GWAS p value thresholds using genetic data obtained from 2586

291 fidence osteoclast eQTL across multiple GWAS P value thresholds.

292 c, European or Asian populations, at various p value thresholds.

293 bilateral groups were combined to an overall P value using Fisher's method for combining P values.

294 were judged significant when the two-tailed P value was less than .05.

295 sided false discovery rate adjusted (FDRadj) p value was less than 0.025.

296 h logistic regression analysis, and critical P values were additionally assessed by using the false d

297 se category was analyzed separately, and the P values were adjusted for multiple comparisons.

298 Dissociation constants (pK(a)) and log P values were measured for the obtained compounds or the

299 18)O(P) values changed, and lower delta(18)O(P) values were associated with higher soil pH values.

300 P values work well if we interpret them as an index of c